BPF: Biocidal product families

Danielle van Corven-Kloosterman
ECHA Biocides Stakeholder Day October 2019
Diversey is a provider of cleaning, sanitation and maintenance products, systems and services that efficiently integrate chemicals, machines and sustainability programs for e.g. facility management, health care, hospitality, retail and food service; in addition to food and beverage.

Headquartered in Fort Mill, South Carolina, USA, Diversey employs approximately 9,000 people globally, generating net sales of approximately $2.6 billion in 2017.
Note for guidance link

CA-July19-Doc4.2-Final

https://circabc.europa.eu/d/a/workspace/SpacesStore/71a22409-076c-4f2d-affede-dea810f128fd/CA-July19-Doc.4.2-Final%20%20Guidance%20note%20%20on%20BPF%20concept.docx
1. BACKGROUND AND PURPOSE OF THE DOCUMENT
2. RELEVANT PROVISIONS AND PROPOSED WAY FORWARD
3. PRACTICAL IMPLEMENTATION
4. APPLICABILITY OF THE WG RECOMMENDATIONS
5. ACTION REQUESTED
6. ANNEXES
   1. Gradual approach for preparing a pre-submission meeting
   2. Examples of the proposed approach on “Similar composition”
   3. Example of meta-SPC with grouping of co-formulants
   4. Excel application to assist on decision regarding the similarity of uses
   5. Exception for similarity of uses
   6. Example of similar level of risk and efficacy
   7. Overview of the approach to group biocidal products in a biocidal product family
   8. Q&A on the implementation of the BPF concept
3. PRACTICAL IMPLEMENTATION

3.1. Best practice in pre-submission meeting

3.2. Assessment of similarity in BPF by applicants
   3.2.1. Decision tree for assessment of similarity
   3.2.2. Similarity of composition within varied composition
   3.2.3. Similarity of uses
   3.2.4. Similar levels of risk and efficacy

3.3. Splitting of families for ongoing applications

3.4. Post-authorisation notification of new products
3. PRACTICAL IMPLEMENTATION

3.1. Best practice in pre-submission meeting

3.2. Assessment of similarity in BPF by applicants
   3.2.1. Decision tree for assessment of similarity
   3.2.2. Similarity of composition within varied composition
   3.2.3. Similarity of uses
   3.2.4. Similar levels of risk and efficacy

3.3. Splitting of families for ongoing applications

3.4. Post-authorisation notification of new products
Pre submission meeting + Annex I

• **Step 1: Contact refMS/eCA**
  - ASAP but not later then 18 months prior to the submission
  - For Union: eCA agreement signature

• **Step 2: Discuss with your refMS/eCA**
  - Meeting
  - Present you family
    - Meta structure and products
    - Actives and substances of concern
    - Intended uses
    - PTs
    - User category/ies
  - Present your testing strategy
  - Risk assessment approach
3. PRACTICAL IMPLEMENTATION

3.1. Best practice in pre-submission meeting

3.2. Assessment of similarity in BPF by applicants
   3.2.1. Decision tree for assessment of similarity
   3.2.2. Similarity of composition within varied composition
   3.2.3. Similarity of uses
   3.2.4. Similar levels of risk and efficacy

3.3. Splitting of families for ongoing applications

3.4. Post-authorisation notification of new products
Similar composition Define the structure of the BPF (MetaSPCs/ uses) and define the backbone composition of the BPF. Assess similarity of composition according to Section 3.2.2 of this document

Similar uses - Assess similarity of uses according to Section 3.2.3 of this document

Similar level of risk and efficacy
Considering the structure of the family as defined in the previous step, assess similar level of risk and efficacy according to Section 3.2.4 of this document

Re-define the structure of the BPF in order to meet the similarity criteria

The BPF meets the similarity criteria
3.1. Best practice in pre-submission meeting

3.2. Assessment of similarity in BPF by applicants

3.2.1. Decision tree for assessment of similarity

3.2.2. Similarity of composition within varied composition

3.2.3. Similarity of uses

3.2.4. Similar levels of risk and efficacy

3.3. Splitting of families for ongoing applications

3.4. Post-authorisation notification of new products

Similar composition: Define the structure of the BPF (MetaSPCs/ uses) and define the backbone composition of the BPF. Assess similarity of composition according to Section 3.2.2 of this document.

Similar uses: Assess similarity of uses according to Section 3.2.3 of this document.

Similar level of risk and efficacy: Considering the structure of the family as defined in the previous step, assess similar level of risk and efficacy according to Section 3.2.4 of this document.

If both criteria are met, the BPF meets the similarity criteria.
Box 1: Similarity of composition within varied composition

Similarity of composition
-> Backbone composition

Within varied composition
-> Grouping of co-formulants
Box 1: Similarity of composition within varied composition +Annex 2

Backbone composition “Each individual member of the BPF should contain the same basic set of ingredients, which is essential to formulate all products within the biocidal product family. Individual products may still contain additional ingredients to comply with the needs for some envisaged individual uses.”

Refers to the actives and co-formulants needed to formulate any individual product in the family (e.g. solvent)

Not for easy exchangeable co-formulants (e.g. perfumes, dyes, pigment)

Exemptions: Carrier-based products, Concentrates which only consists of AS
Grouping of co-formulants

- Co-formulants need to be clearly defined in level 2 of the family
  - What is the worst case for risk or efficacy?
- Group some co-formulants together:
  - have the same function,
  - have the same impact on the classification
  - have the same impact on the level of risk and efficacy of the formulation.

- Allowed, but not mandatory
- By applicant sound technical arguments and where necessary data
## Grouping of co-formulants (Annex 3)

<table>
<thead>
<tr>
<th>Function</th>
<th>Level 2 - Meta SPC</th>
<th>Level 3 - Individual Products within the meta SPC</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>min(%)</td>
<td>max(%)</td>
</tr>
<tr>
<td>Active Substance</td>
<td>0.15</td>
<td>0.50</td>
</tr>
<tr>
<td>Complexing Agents</td>
<td>1.00</td>
<td>3.00</td>
</tr>
<tr>
<td>Thickeners</td>
<td>0.50</td>
<td>1.00</td>
</tr>
<tr>
<td>Emollients</td>
<td>4.12</td>
<td>9.20</td>
</tr>
<tr>
<td>Wetting Agents</td>
<td>0.15</td>
<td>2.6</td>
</tr>
<tr>
<td>Solvent</td>
<td>83.7</td>
<td>94.13</td>
</tr>
</tbody>
</table>
3. PRACTICAL IMPLEMENTATION

3.1. Best practice in pre-submission meeting

3.2. Assessment of similarity in BPF by applicants
   3.2.1. Decision tree for assessment of similarity
   3.2.2. Similarity of composition within varied composition
   3.2.3. Similarity of uses
   3.2.4. Similar levels of risk and efficacy

3.3. Splitting of families for ongoing applications

3.4. Post-authorisation notification of new products

---

**Similar composition:** Define the structure of the BPF (MetaSPCs/uses) and define the backbone composition of the BPF. Assess similarity of composition according to Section 3.2.2 of this document.

**Similarity criteria met?**
- Yes
- No

**Similar uses:** Assess similarity of uses according to Section 3.2.3 of this document.

**Similarity criteria met?**
- Yes
- No

**Similar level of risk and efficacy:** Considering the structure of the family as defined in the previous step, assess similar level of risk and efficacy according to Section 3.2.4 of this document.

**Similarity criteria met?**
- Yes
- No

---

The BPF meets the similarity criteria.
Box 2 Similarity of Uses

Criteria to assess whether a pair of uses within a BPF is similar are included in a decision tree.
Similarity of Uses – Focus Main group I & II

Both uses belong to Main Groups 1 and 2

Yes → Same PT

No → Possible to consider uses as similar (on a case by case basis to be confirmed by applying the criteria on similar level of risk and efficacy)

Same PT

Yes → Both uses are applied on the same type of object (See recital 48 below).

No → Same use pattern (See recital 49 below)

Both uses are applied on the same type of object (See recital 48 below).

Yes → Uses considered similar Case by case (See recital 50 below). Consider application of exceptions (Annex V)

No → Possible to consider uses as similar (on a case by case basis to be confirmed by applying the criteria on similar level of risk and efficacy)
Similarity of Uses – Focus Main group I & II

Same type of "object“ within the same PT (Recital 48):

a) Application directly on human or animal skin.
b) Hard surfaces such as for instance walls, floor, equipment, pipework, inner surfaces, soft surfaces such as for instance soft furnishing, textile disinfection, and other surfaces such as for instance hatching eggs, litter, surfaces associated with the housing and transportation of animals.
c) Construction materials and hard surfaces.
d) Laundry and textiles.
e) Air and room disinfection (vaporised biocide).
f) Products incorporated in treated articles.
g) Water (or liquid) matrix (any kind of water)
h) Surfaces in contact with water (or other liquid) and water (or liquid) matrix (other than waste water). Air condition systems, washing machines and crate washers.
i) Chemical toilets
j) Hospital waste
k) Soil
Similarity of Uses – Focus Main group I & II

Both uses belong to Main Groups 1 and 2

Yes

Same PT

Yes

Both uses are applied on the same type of object (See recital 48 below).

Yes

No

Uses considered similar Case by case (See recital 50 below). Consider application of exceptions (Annex V).

Same use pattern (See recital 49 below)

Yes

Possible to consider uses as similar (on a case by case basis to be confirmed by applying the criteria on similar level of risk and efficacy)

No
Same use pattern for different PTs (Recital 49):

a) Application directly on human or animal skin.
b) Application in pipework / inner surfaces (CIP)/ surface in contact with water (or other liquid)
c) Application on hard or soft surfaces/ instruments/ equipment (other than hatching eggs, surfaces associated with the housing and transportation of animals and application via room disinfection)
d) Application on laundry and textiles
e) Air disinfection and application for room disinfection (vaporised biocide)
f) Products incorporated in treated articles
g) Application on a water matrix (other than waste water, manure)
h) Application on waste water and manure
Similarity of Uses – Focus Main group I & II

Both uses belong to Main Groups 1 and 2

Yes → Same PT

Yes → Both uses are applied on the same type of object (See recital 48 below).

No → No

Yes → Yes

No → Same use pattern (See recital 49 below)

No → Yes

Possible to consider uses as similar (on a case by case basis to be confirmed by applying the criteria on similar level of risk and efficacy)

No → No

Uses considered similar Case by case (See recital 50 below). Consider application of exceptions (Annex V)
Exceptions that are be considered as similar on a case by case basis (Recital 50):

a) PT1 (Human hygiene) and the following uses:
   • PT2 and PT4: Disinfection of hard surfaces instrument and equipment.
   • PT2: Products to be incorporated in textiles, tissues and materials with the purpose of producing treated articles with disinfecting properties.

c) PT2 disinfectants for pipework/inner surfaces (CIP)/ Surface in contact with water and PT3 products used for disinfection of the materials and surfaces in contact with water associated with the housing or transportation of animals (e.g. in aquaculture).

Etc

h) Other use patterns that might be agreed by the CG.
Box 2 Similarity of Uses

Criteria to assess whether a pair of uses within a BPF is similar are included in a decision tree:

An automated tool in the form of a matrix has been developed to assist on the application of the criteria (Annex 4):

Some flexibility is possible in order to avoid unnecessary submissions: in each family a maximum of **two** pairs of uses that are **a priori** considered as "non-similar" is allowed. (Annex 5)
3. PRACTICAL IMPLEMENTATION

3.1. Best practice in pre-submission meeting

3.2. Assessment of similarity in BPF by applicants
   3.2.1. Decision tree for assessment of similarity
   3.2.2. Similarity of composition within varied composition
   3.2.3. Similarity of uses
   3.2.4. Similar levels of risk and efficacy

3.3. Splitting of families for ongoing applications

3.4. Post-authorisation notification of new products

Similar composition: Define the structure of the BPF (MetaSPC/ uses) and define the backbone composition of the BPF. Assess similarity of composition according to Section 3.2.2 of this document

Similarity criteria met

Similar uses: Assess similarity of uses according to Section 3.2.3 of this document

Similarity criteria met

Similar level of risk and efficacy: Considering the structure of the family as defined in the previous step, assess similar level of risk and efficacy according to Section 3.2.4 of this document

Similarity criteria met

The BPF meets the similarity criteria
3.2.4. Similar levels of risk and efficacy + Annex 6 and 7

One core assessment on significant portion of family.

Worst case assessment for

- Risk assessments
- Efficacy

for every use.
3.2.4. Similar levels of risk and efficacy + Annex 6 and 7

Extension possible if inclusion would significantly restrict overall authorization.

E.g. for different fields of use (e.g. outdoor use)

Subset possible if where the efficacy or a safe use cannot be supported over the whole composition range of the core.

E.g. for different user categories (e.g. non-professional user).
3.2.4. Similar levels of risk and efficacy + Annex 6 and 7

75. However, in order to ensure a manageable size of the BPF such extensions triggering a complete re-assessment of all BPF parameters independent from the core assessment are not acceptable. Only extensions which are limited to a number of refinements of the original core assessment are acceptable.

78. ...MS can accept the inclusion of subsets and extensions in a BPF.

80. MS should generally accept only extensions and subsets requiring overall not more than three refinements per family (via subsets and/or extensions). ... subsets considered as necessary in order to support para. 77 of Annex VI of the BPR are supported and would not be included as part of these three refinements ...
3. PRACTICAL IMPLEMENTATION

3.1. Best practice in pre-submission meeting

3.2. Assessment of similarity in BPF by applicants
   3.2.1. Decision tree for assessment of similarity
   3.2.2. Similarity of composition within varied composition
   3.2.3. Similarity of uses
   3.2.4. Similar levels of risk and efficacy

3.3. Splitting of families for ongoing applications

3.4. Post-authorisation notification of new products
Splitting of a Family during evaluation, mutual recognition or peer review is possible: e.g. not having either similar uses, composition or level of efficacy or risk.

Keep in mind: This guidance could be applied for applications submitted before 01/10/2019 if the applicants agree.

Initial application continues

New application has to be made for the “splitted” parts:
• All products still covert by transition provision (BPR article 89)
• Review concluded in the same “original” time path
• Fees for this new application? eCA/refMS fee and ECHA fee
1. BACKGROUND AND PURPOSE OF THE DOCUMENT
2. RELEVANT PROVISIONS AND PROPOSED WAY FORWARD
3. PRACTICAL IMPLEMENTATION
4. APPLICABILITY OF THE WG RECOMMENDATIONS
5. ACTION REQUESTED
6. ANNEXES
   1. Gradual approach for preparing a pre-submission meeting
   2. Examples of the proposed approach on “Similar composition”
   3. Example of meta-SPC with grouping of co-formulants
   4. Excel application to assist on decision regarding the similarity of uses
   5. Exception for similarity of uses
   6. Example of similar level of risk and efficacy
   7. Overview of the approach to group biocidal products in a biocidal product family
   8. Q&A on the implementation of the BPF concept
To think about ...

- Family concept has more restrictions versus a single registrations

- Family needs more explaining
  - Where to explain family in PAR template
  - Where to explain Core/Extension/Subsets
  - SPC editor versus grouping of ingredients

- For already submitted dossier, guidance is not applicable but rMS/eCA might not agree with applicants view on either similar uses, similar composition or similar level of efficacy or risk
Thank you!

Daniëlle van Corven-Kloosterman
Diversey Europe
Operations BV